DaBomb Protein Biotech Corp.

Total Valuation

DaBomb Protein Biotech Corp. carries a market capitalization of 1.19B, placing it among publicly traded companies globally. Its enterprise value stands at 1.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

DaBomb Protein Biotech Corp. currently has 71.94M shares outstanding.

Valuation Ratios

DaBomb Protein Biotech Corp. trades at a trailing price-to-earnings ratio of 384.38. The price-to-sales ratio is 4.34, and the price-to-book ratio stands at 1.83.

Enterprise Valuation

On an enterprise value basis, DaBomb Protein Biotech Corp. trades at an EV/EBITDA multiple of 451.80 and an EV/FCF ratio of 16.53. The EV/Sales ratio of 3.97 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 451.80 provides insight into valuation relative to core operating earnings.

Financial Position

DaBomb Protein Biotech Corp. maintains a current ratio of 3.31, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.31, indicating elevated leverage, while an interest coverage ratio of -0.13 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, DaBomb Protein Biotech Corp. has paid -975,000.00 in income taxes, reflecting an effective tax rate of 76.23.

Stock Price Statistics

DaBomb Protein Biotech Corp.'s stock has declined approximately -16.24365% over the past 52 weeks. The 50-day moving average sits at 16.32, while the 200-day moving average is 18.64.

Income Statement

Over the trailing twelve months, DaBomb Protein Biotech Corp. generated 298.10M in revenue and converted that into -13.12M in net income, yielding earnings per share of -0.18. EBITDA reached -516,000.00, while operating income came in at -516,000.00.

Balance Sheet

DaBomb Protein Biotech Corp. holds 249.18M in cash and equivalents against 137.23M in total debt, resulting in a net debt position of -86.81M. Total book value stands at 707.95M, with working capital of 388.01M providing operational flexibility.

Cash Flow

DaBomb Protein Biotech Corp. produced 16.97M in operating cash flow over the past twelve months. After subtracting -50.95M in capital expenditures, free cash flow totaled -33.98M - equivalent to -0.49 per share.

Margins

DaBomb Protein Biotech Corp. operates with a gross margin of 20.84, reflecting its pricing power and cost economics. The operating margin of -0.17 and net profit margin of -4.40 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

DaBomb Protein Biotech Corp.'s most recent stock split took place on December 1, 2021 with a 1000:1019 split ratio.

Scores

DaBomb Protein Biotech Corp. posts an Altman Z-Score of 4.51, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.